Information Provided By:
Fly News Breaks for February 2, 2017
GALE
Feb 2, 2017 | 08:08 EDT
Maxim analyst Jason Kolbert downgraded Galena to Hold from Buy given the uncertainty he sees for its path forward following the resignation of CEO Mark Schwartz. While he believes that NeuVax and GALE-401 have potential in breast cancer and essential thrombocythemia, respectively, the uncertainty about the company's future and no visibility on timing around resolution lead him to the downgrade, he tells investors.
News For GALE From the Last 2 Days
There are no results for your query GALE